XML 71 R16.htm IDEA: XBRL DOCUMENT
v3.3.0.814

Redeemable Convertible Preferred Stock and Common Stock | 9 Months Ended
--- | ---
Sep. 30, 2015
Text Block [Abstract] |
Redeemable Convertible Preferred Stock and Common Stock | 10. Redeemable Convertible Preferred Stock and Common Stock Redeemable Convertible Preferred Stock consisted of the following at December 31, 2014:
|  | Shares |  |  |  |  |  |  |  |  | Common Stock Issuable upon Conversion |
|  | Preferred Stock Designated |  |  | Issued and Outstanding |  |  | Liquidation Preference |  |  | Carrying Value |  |
Series B |  |  | 180,980,200 |  |  |  | 41,788,790 |  |  | $ | 20,894 |  |  | $ | 20,894 |  |  |  | 2,477,032 |
Seed |  |  | 1,219,508 |  |  |  | 1,219,508 |  |  |  | 1,331 |  |  |  | 1,331 |  |  |  | 72,293 |
Series A-4 |  |  | 1,307,190 |  |  |  | 1,307,190 |  |  |  | 4,000 |  |  |  | 4,000 |  |  |  | 474,201 |
Series B-1 |  |  | 18,687,554 |  |  |  | 18,687,554 |  |  |  | 9,344 |  |  |  | 9,344 |  |  |  | 1,107,706 |
Junior Seed |  |  | 410,000 |  |  |  | 410,000 |  |  |  | 820 |  |  |  | 4 |  |  |  | 24,307 |
|  |  | 202,604,452 |  |  |  | 63,413,042 |  |  | $ | 36,389 |  |  | $ | 35,573 |  |  |  | 4,155,539 |
On March 13, 2015, pursuant to the Merger Agreement, and as a condition to closing the Merger, the Company entered into a Preferred Stock Conversion Agreement, under the terms of which, immediately prior to the completion of the Merger, each series of the Pulmatrix Operating’s preferred stock would be automatically converted into shares of Pulmatrix Operating’s common stock. On June 15, 2015, prior to the Effective Time, Pulmatrix Operating had 63,413,042 shares of Redeemable Convertible Preferred Stock outstanding, which were convertible into 70,105,854 shares (pre-Reverse Stock Split and before giving effect to the Exchange Ratio) of Pulmatrix Operating common stock. Immediately prior to the completion of the Merger, the outstanding shares of Redeemable Convertible Preferred Stock were converted into 70,105,854 shares (pre-Reverse Stock Split and before giving effect to the Exchange Ratio) of Pulmatrix Operating common stock. Pulmatrix Operating Private Placement On June 15, 2015, immediately prior to the Effective Time, pursuant to a securities purchase agreement between the Company and certain existing investors of the Company dated March 13, 2015, the Company sold to such investors 24,538,999 units, with each unit consisting of (i) one share of Pulmatrix Operating’s common stock and (ii) a warrant representing the right to purchase 2.193140519 shares of Pulmatrix Operating common stock at an exercise price of $0.448266 per share (each pre-Reverse Stock Split and before giving effect to the Exchange Ratio), for aggregate gross proceeds of $10,000 (the “Pulmatrix Operating Private Placement”). Upon the Effective Time, the Pulmatrix Operating common stock underlying the units was exchanged for an aggregate of 1,454,553 shares of Company Common Stock, and the warrants underlying the units were converted into warrants to purchase an aggregate of 3,190,030 shares of Company Common Stock at an exercise price of $7.563 per share. The proceeds from the issuance of the units were allocated between the Company Common Stock and the warrants based on their relative fair values. Ruthigen Private Placement Immediately after the Effective Time, the Company closed a private placement of 379,387 shares of Company Common Stock at a price of $6.875 per share in a private placement for aggregate gross proceeds of approximately $2.6 million (the “Ruthigen Private Placement”).

X
- Definition Temporary Equity Disclosure. + References No definition available. + Details
Name: | pulm_TemporaryEquityDisclosureTextBlock
Namespace Prefix: | pulm_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration